Objectives: The aim of this study was to evaluate CHROMagar CTX (CHROMagar France), a novel agar for the selective isolation of Enterobacteriaceae expressing the bla CTX-M gene in the presence of enteric bacteria expressing AmpC enzymes.
Introduction
Third-generation cephalosporins were introduced into human and veterinary medicine in the early 1980s and shortly after their introduction resistance to them was reported. 1 Extendedspectrum b-lactamase (ESBL) enzymes confer resistance to a range of cephalosporin antibiotics (e.g. cefalexin, cefotaxime and ceftazidime), and until the end of the 1990s, most ESBLs were almost exclusively TEM and SHV variants found in enterobacterial species such as Klebsiella.
2, 3 Since then, CTX-M-ESBL-producing Escherichia coli have emerged as a significant and developing problem in many parts of the world, occurring in patients in the community as well as in those with recent hospital contact.
2 There are currently over 60 different CTX-M b-lactamases recognized and the diversity and increasing prevalence of CTX-M-type ESBLs pose a serious threat to the clinical use of third-generation cephalosporins for the treatment of severe infections. 3 With respect to CTX-M-ESBL-producing E. coli in animals, in 2000-01 the first CTX-M-ESBL-producing E. coli were isolated from healthy chickens in Spain 4 and from cattle in Japan. 5 Since then, CTX-M-ESBL-producing bacteria have been isolated from a wide range of animals in many countries, including cattle, poultry and swine in France, 6 cattle in Hong Kong, 7 chickens, ducks, pigs and partridges in China, 8 horses in the Netherlands, 1 cattle in the UK 9 and pets and wild animals in Portugal. In many studies aiming to isolate bacteria carrying ESBLs from a mixed bacterial flora, cefotaxime has been added to selective agar at 1 mg/L 10 or 2 mg/L, 5, 7, 12, 13 and ceftazidime has also been used. 13, 14 In comparisons between a novel chromogenic agar (ESBL-Bx; bioMérieux) and MacConkey agar supplemented with 2 mg/L ceftazidime for the selective isolation and presumptive identification of ESBL bacteria, natural AmpC strains as well as non-ESBL-producing Klebsiella oxytoca gave rise to the most false-positives and this was also observed with other selective agars incorporating either cefotaxime or ceftazidime. 14 The difficulty in distinguishing CTX-M strains from other resistant organisms limits the capacity to carry out large epidemiological studies for the prevalence of CTX-M strains.
Given their increasing global prevalence and importance, the aim of this study was to evaluate CHROMagar CTX (initially for veterinary use) for the selective isolation and presumptive identification of CTX-M strains in the presence of strains expressing an AmpC b-lactamase.
Materials and methods

Strains
A panel of 150 strains of human (n ¼ 78) and bovine (n ¼ 64) origin as well as control strains (n ¼ 8) were assembled for the evaluation of CHROMagar CTX for selectively isolating bacteria expressing a bla CTX-M gene while inhibiting AmpC strains ( Table 1 ). The strains of human origin were obtained from the Public Health Laboratory, UK, and from the University of Wales Hospital, UK, and were deliberately obtained to provide a variety of CTX-M-ESBL-producing, non-CTX-M-ESBL-producing and AmpC types. None of the strains of human origin was known to be the ST131 UPEC clone. The strains of bovine origin were from the collection of strains at the Veterinary Laboratories Agency.
For tests with MAST ESBL ID discs, E. coli NCTC 10418 was used as a negative control and NCTC 13351, 13352 and 13353 were used as ESBL-positive controls. For the ampC multiplex PCR, E. coli DH10B, PSKL54 and J53PMG252 were PCR-positive controls for MOX, ACC and FOX groups, respectively, Morganella morganii CB23/2 was the PCR-positive control strain for the DHA group and Salmonella 197511-0 was the PCR-positive control strain for the CIT group; 15 these strains were included in the media testing. The ampC genes within the groups ACC, CIT, DHA, FOX and MOX are shown in the footnotes to Table 1 . Multiplex PCR for bla OXA, bla SHV and bla TEM was performed with suitable positive and negative control strains from the panel of test strains for each gene.
Five representative CTX-M-positive strains (in equal proportions) comprising CTX-M types 1 and 14 and five AmpC-positive strains (in equal proportions) comprising strains positive for the CIT, DHA, ACC and FOX groups of ampC genes 15 were used to spike bovine faeces to determine recovery rates from different media.
Antibiotics and chemicals
All antibiotics and chemicals were obtained from Sigma-Aldrich (Poole, Dorset, UK).
Phenotypic tests
ESBL phenotypic tests using MAST ESBL ID cefepime, cefotaxime, cefpodoxime and ceftazidime discs with and without clavulanate (MAST group Ltd, UK) were performed according to the manufacturer's instructions. A culture that was ESBL-positive with at least one pair of discs was taken as being 'ESBL phenotype positive'. MICs of ceftazidime and cefotaxime were determined by the method of the BSAC. 16 
PCR
All strains in the panel were tested for the presence of bla CTX-M genes using universal CTX-M primers as described previously. 17 All strains in the panel were also tested for plasmid-mediated ampC genes as described previously. 15 For the detection of bla OXA , bla SHV and bla TEM genes, a multiplex PCR was designed that gave 313, 212 and 426 bp products, respectively. Primers for the multiplex PCR were as follows:
. PCRs were performed using 44 mL of Thermo Scientific PCR master mixture containing 2.0 mM MgCl 2 (ABgene w UK) and 1 mL of each primer at a concentration of 25 mM. The PCR program consisted of an initial denaturation step at 948C for 5 min, followed by 35 cycles of denaturation at 948C for 30 s, annealing at 628C for 1 min and primer extension at 728C for 1 min, followed by a final extension step at 728C for 10 min.
Evaluation of CHROMagar CTX and other media using the panel of strains
CHROMagar ECC was used as the basal medium to which the supplement CHROMagar CTX (CHROMagar, France) was added. The sensitivity and specificity of CHROMagar CTX for the selective growth of bla CTX-M strains while inhibiting other strains was calculated and compared with that for CHROMagar ECC with the addition of 1, 2, 4 and 8 mg/L of either cefotaxime or ceftazidime and with bioMérieux ESBL-Bx agar.
Evaluation of CHROMagar CTX agar and other media using spiked and unspiked ('natural') faecal samples Using the methodology described previously, 9 CHROMagar CTX was used to isolate presumptive E. coli strains potentially expressing the bla CTX-M gene from a total of 342 farm animal faecal/caecal samples. Briefly, 1 g of faecal/caecal sample was placed into 9 mL of buffered peptone water, which was incubated overnight at 378C. The resulting growth was streaked (10 mL) onto agar, which was also incubated overnight at 378C.
Isolation from CHROMagar CTX was compared with isolation from CHROMagar þ 1 mg/L cefotaxime or ceftazidime (246 of the unspiked animal faeces), CHROMagar þ 2 mg/L cefotaxime (48 of the unspiked animal faeces) and CHROMagar ECC with the addition of 0, 2 or 8 mg/L cefotaxime or bioMérieux ESBL-Bx agar (spiked bovine faeces). Isolates were stored on Dorset egg slopes prior to genotypic and phenotypic tests.
Stability of CHROMagar CTX
The stability of CHROMagar CTX when stored in a refrigerator at 2-88C was monitored over a 2 month period by weekly plating out of 10 control strains. The agar was deemed to show acceptable performance while it inhibited the four AmpC strains and the four CTX-M-negative strains but allowed growth of two CTX-M-positive strains.
Calculation of sensitivity and specificity
Sensitivity for an agar was calculated as the number of test positives (i.e. all strains with the CTX-M gene that grew on the agar) divided by the number of 'gold standard' positive strains (i.e. all strains positive for the CTX-M gene) times 100. Specificity for a given test or agar was calculated as the number of test negatives (i.e. strains without the CTX-M gene that did not grow on the agar) divided by the number of 'gold standard' negatives (i.e. all strains negative for the CTX-M gene) times 100. Table 2 of their paper. Each of these primers will detect several ampC genes: i.e. MOX primers, MOX1, MOX2, CMY1, CMY8 to CMY11; CIT primers, LAT1 to LAT4, CMY2 to CMY7, BIL1; DHA primers, DHA1 and DHA2; ACC primers, ACC; and FOX primers, FOX1 to FOX5B. c ESBL type not identified by sequencing.
Results
Performance of CHROMagar CTX with the panel of strains
While not all of the strains in the panel were sequenced with respect to their specific CTX-M, non-CTX-M-ESBL or AmpC type, the panel was fully characterized with respect to key characteristics for the media evaluation, i.e. the presence of bla CTX-M, bla OXA , bla SHV and bla TEM genes, ampC genes, some MICs and the ESBL phenotype. Additionally, many strains were sequenced to show that the panel did represent a diverse selection of CTX-M types and non-CTX-M-ESBLs.
The apparent discrepancies between numbers of strains with bla OXA , bla SHV and bla TEM in Tables 1 and 2 occur because the  figures in Table 1 denote strains positive by PCR, but where the ESBL has not been confirmed by sequencing the PCR product, whereas in Table 2 , the non-CTX-M-ESBL type is only given if confirmed by sequencing.
CHROMagar CTX was shown to be superior to all other agars tested with respect to selective growth of bla CTX-M -positive strains while inhibiting AmpC strains (Tables 2 and 3 ).
The MIC range of cefotaxime and ceftazidime for the CTX-M-ESBL-producing strains (n ¼ 70) was 4 to .128 mg/L and 0.13 to .128 mg/L, respectively. However, the cefotaxime MICs for all but one isolate were .8 mg/L and were .64 mg/L for 67% of the isolates. The MIC range of cefotaxime and ceftazidime for the non-CTX-M-ESBL-producing strains (n ¼ 80) was 0.13 to .128 mg/L, but the cefotaxime and ceftazidime MICs for 61% and 43% of the strains, respectively, were ,16 mg/L.
Only 5 of 37 AmpC strains grew on CHROMagar CTX compared with 28 of 37 AmpC strains on bioMérieux ESBL-Bx agar and between 23 and 34 of 37 AmpC strains on all the other agars (Table 2) . One CTX-M strain that also had a CIT class ampC gene grew on CHROMagar CTX.
CHROMagar CTX showed 100% sensitivity and 64.2% specificity for growth of the bla CTX-M strains when compared with the rest of the panel and 100% sensitivity and 88.9% specificity when compared just with the AmpC strains, and this was superior to CHROMagar ECC with the addition of different concentrations of either cefotaxime or ceftazidime or bioMérieux ESBL-Bx agar ( Table 3 ). The reduced specificity of CHROMagar CTX for this panel of strains was mainly due to some non-CTX-M-ESBL producers growing (Tables 2 and 3) . Further details of all non-CTX-M-ESBL producers growing on CHROMagar CTX can be seen in Table 4 . The cefotaxime MICs for all of these strains were .0.5 mg/L and most had an ESBL phenotype and bla OXA, bla SHV or bla TEM genes as detected by multiplex PCR.
K. oxytoca strains can be falsely identified as ESBL-positive as the activity of cefotaxime and cefepime, and rarely Isolation of CTX-M bacteria from animal faeces ceftazidime, can be potentiated 8-fold or higher with clavulanate. 18 Although the control strain of K. oxytoca K1 grew on bioMérieux ESBL-Bx agar and on CHROMagar EEC containing 1 mg/L cefotaxime, it did not grow on CHROMagar CTX.
Performance of CHROMagar CTX for isolation of CTX-M strains from spiked bovine faeces
Without any added inhibitors, CHROMagar ECC isolated mainly bla CTX-M -negative strains from spiked bovine faeces. CHROMagar CTX was superior to the other agars tested for isolation of CTX-M strains from spiked bovine faeces, particularly where there were low numbers of CTX-M strains in the presence of AmpC strains as shown in Table 5 . With enrichment, it was possible to selectively isolate bla CTX-M -positive strains from bovine faeces using CHROMagar CTX-M when they were present at only 10 cfu/g of faeces, even in the presence of 10 000 cfu/g of faeces of AmpC strains and in the presence of other normal faecal flora.
Performance of CHROMagar CTX for isolation from 'natural' faeces
For both groups of 'natural' animal faeces, CHROMagar CTX was superior to the other agars tested for the isolation of CTX-M strains.
For 48 of the 'natural' animal faecal samples, of the 51 and 84 colonies (in some cases, more than one colony type was examined per sample) isolated using CHROMagar CTX or CHROMagar þ 2 mg/L cefotaxime, respectively, 100% and 53%, respectively, were positive for the CTX-M gene.
For the further 246 'natural' animal faecal samples examined, 76, 66 and 10 yielded growth on CHROMagar þ 1 mg/L cefotaxime or ceftazidime or on CHROMagar CTX, respectively, and phenotypic tests showed that 18%, 23% and 100%, respectively, of positive plates yielded an ESBL-positive colony. Of the ESBL-positive strains isolated from CHROMagar þ 1 mg/L cefotaxime or ceftazidime or on CHROMagar CTX, 57% (8 isolates), 13% (2 isolates) and 90% (9 isolates), respectively, were CTX-M-positive.
For both spiked and 'natural' animal faeces, of 342 samples plated on CHROMagar CTX, 106 yielded growth, and for a single colony taken from each plate, 90.1% were CTX-M-positive. The focus of this study was CTX-M-ESBL-producing strains and the characteristics of the 9.9% CTX-M-negative isolates that grew on the CHROMagar CTX were not further tested.
Stability of CHROMagar CTX
CHROMagar CTX was found to be stable for up to 2 months when stored at 2 -88C.
Discussion
In view of the importance of ESBLs and the specific importance of CTX-M-type ESBLs, it is highly pertinent to investigate the possibility of developing a medium that will give good sensitivity and specificity for the isolation of bacteria expressing CTX-M-type ESBLs in the presence of bacteria expressing AmpC enzymes. Such a medium would help to facilitate epidemiological studies to determine the prevalence of strains harbouring the bla CTX-M gene, especially in some animal species where AmpC-producing commensal E. coli can be encountered reasonably frequently in the enteric flora. Most in-house media comprise selective agars supplemented with 1-2 mg/L cefotaxime or ceftazidime. However, at least two studies comment on the limitations of in-house or commercial media in that they do not inhibit AmpC strains or K. oxytoca strains, 13, 14 and that growth of AmpC strains can impair the isolation of CTX-M-ESBL-producing strains. In studies where it is necessary to specifically isolate CTX-M-ESBL-producing strains, there is therefore a need for a medium that will inhibit AmpC strains and K. oxytoca strains. This study has provided such an agar that has been evaluated against a relevant panel of strains and against spiked and 'natural' animal faecal samples. This agar is now available commercially as CHROMagar CTX (CHROMagar). While ideally an agar for isolating bacteria should be 100% sensitive and specific, this is an unrealistic goal when isolating bacteria from such complex matrices as faeces and when attempting to isolate a specific ESBL type. A very good sensitivity can be of limited advantage if the specificity is poor, as demonstrated by our results with 246 'natural' animal faeces. The results from these samples demonstrated how the use of CHROMagar CTX could markedly reduce the number of primary culture plates and number of colonies that would need to be examined to detect CTX-M-ESBL-producing strains in faecal samples, compared with using the same agar, but supplemented with 1 mg/L cefotaxime or ceftazidime.
While the CHROMagar CTX could also be used for the isolation of many ESBLs that do not belong to the CTX-M group, it would inhibit some of these strains, since it was specifically designed for the isolation of CTX-M-ESBL-producing strains. The cefotaxime MICs for the non-CTX-M strains that grew on the CHROMagar CTX were all .0.5 mg/L and all of these strains were ESBL producers with the exception of five strains of Pseudomonas and two strains positive for CMY. CHROMagar CTX was shown to be superior to other agars for the isolation of CTX-M-ESBL-producing strains and, as such, should be of use in studies where the goal is to isolate CTX-M-ESBL-producing strains.
This medium may also have applications in the medical field, where screening for ESBLs of the CTX-M family in enteric bacteria in the presence of enteric bacteria expressing AmpC enzymes is required. In these situations, other ESBLs that do not belong to the CTX-M group may be inhibited.
In conclusion, we have evaluated CHROMagar CTX for the isolation of certain Enterobacteriaceae expressing ESBLs belonging to the CTX-M family, while inhibiting strains expressing AmpC b-lactamases. This validation has been performed with a range of human and animal isolates and with spiked and 'natural' animal faeces, and in all instances, CHROMagar CTX performed better than the other agars with which it was compared.
